Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease

PurposeThe unilateral 6-hydroxydopamine (6-OHDA) lesion rat model is a well-known acute model for Parkinson’s disease (PD). Its validity has been supported by invasive histology, behavioral studies and electrophysiology. Here, we have characterized this model in vivo by multitracer imaging [glucose metabolism and dopamine transporter (DAT)] in relation to behavioral and histological parameters.MethodsEighteen female adult Wistar rats (eight 6-OHDA-lesioned, ten controls) were investigated using multitracer [18F]-fluoro-2-deoxy-D-glucose (FDG) and [18F]-FECT {2′-[18F]-fluoroethyl-(1R-2-exo-3-exe)-8-methyl-3-(4-chlorophenyl)-8-azabicyclo(3.2.1)-octane-2-carboxylate} small animal positron emission tomography (PET). Relative glucose metabolism and parametric DAT binding images were anatomically standardized to Paxinos space and analyzed on a voxel-basis using SPM2, supplemented by a template-based predefined volumes-of-interest approach. Behavior was characterized by the limb-use asymmetry test; dopaminergic innervation was validated by in vitro tyrosine hydroxylase staining.ResultsIn the 6-OHDA model, significant glucose hypometabolism is present in the ipsilateral sensory-motor cortex (−6.3%; p = 4 × 10−6). DAT binding was severely decreased in the ipsilateral caudate-putamen, nucleus accumbens and substantia nigra (all p < 5 × 10−9), as confirmed by the behavioral and histological outcomes. Correlation analysis revealed a positive relationship between the degree of DAT impairment and the change in glucose metabolism in the ipsilateral hippocampus (p = 3 × 10−5), while cerebellar glucose metabolism was inversely correlated to the level of DAT impairment (p < 3 × 10−4).ConclusionsIn vivo cerebral mapping of 6-OHDA-lesioned rats using [18F]-FDG and [18F]-FECT small animal PET shows molecular–functional correspondence to the cortico-subcortical network impairments observed in PD patients. This provides a further molecular validation supporting the validity of the 6-OHDA lesion model to mimic multiple aspects of human PD.

[1]  J. P. Huston,et al.  UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.

[2]  N. Wierup,et al.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.

[3]  E. Broussolle,et al.  Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease , 2001, Neurophysiologie Clinique/Clinical Neurophysiology.

[4]  David Eidelberg,et al.  Metabolic brain networks associated with cognitive function in Parkinson's disease , 2007, NeuroImage.

[5]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[6]  M Samii,et al.  Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG‐PET , 2001, Movement disorders : official journal of the Movement Disorder Society.

[7]  稲次 基希 In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats , 2006 .

[8]  Tetsuya Mori,et al.  Gender differences in cerebral glucose metabolism: a PET study , 2002, Journal of the Neurological Sciences.

[9]  T. Schallert,et al.  Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism , 2000 .

[10]  S. Houle,et al.  In vivo evaluation of [11C]- and [18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. , 1996, Nuclear medicine and biology.

[11]  G. Di Chiara,et al.  Local cerebral glucose utilization after D1 receptor stimulation in 6‐OHDA lesioned rats: Effect of sensitization (priming) with a dopaminergic agonist , 1993, Synapse.

[12]  Patrik Brundin,et al.  Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice , 2005, Behavioural Brain Research.

[13]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  Doris J. Doudet,et al.  Evaluation of the Integrity of the Dopamine System in a Rodent Model of Parkinson’s Disease: Small Animal Positron Emission Tomography Compared to Behavioral Assessment and Autoradiography , 2006, Molecular Imaging and Biology.

[15]  George Maeda,et al.  Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats , 1999, Brain Research.

[16]  J. P. Huston,et al.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.

[17]  G. Cohen Oxy-radical toxicity in catecholamine neurons. , 1984, Neurotoxicology.

[18]  R. C. Collins,et al.  Metabolic effects of unilateral lesion of the substantia nigra , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[20]  K. Gwinn‐Hardy,et al.  The role of radiotracer imaging in Parkinson disease , 2005, Neurology.

[21]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[22]  Jean-Claude Baron,et al.  Executive processes in Parkinson's disease: FDG‐PET and network analysis , 2004, Human brain mapping.

[23]  Simon R. Cherry,et al.  Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease , 2000, Experimental Neurology.

[24]  Z. Susel,et al.  Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  S. Obayashi,et al.  Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats , 2005, Brain Research.

[26]  Gerda Andringa,et al.  Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease , 2005, NeuroImage.

[27]  R. Burke,et al.  6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[28]  O. Isacson,et al.  Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.

[29]  Johan Nuyts,et al.  Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  C. Patlak,et al.  Pentobarbital produces dissimilar changes in glucose influx and utilization in brain. , 1991, The American journal of physiology.

[31]  J. Rinne,et al.  Uptake of 6‐[18F]fluoro‐L‐dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease , 2004, Synapse.

[32]  V. Dhawan,et al.  Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.

[33]  John R. Votaw,et al.  Isoflurane Alters the Amount of Dopamine Transporter Expressed on the Plasma Membrane in Humans , 2004, Anesthesiology.

[34]  Y. Magata,et al.  Alteration of striatal [11C]raclopride and 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats , 2005, Neuroscience Letters.

[35]  A. Dagher,et al.  The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. , 2001, Brain : a journal of neurology.

[36]  V. Sturm,et al.  Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  Jae Seung Kim Metabolic Topography of Parkinsonism , 2007 .

[38]  Klaus Wienhard,et al.  Measurement of glucose consumption using [(18)F]fluorodeoxyglucose. , 2002, Methods.

[39]  C. Verney,et al.  Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study , 1994, Brain Research.

[40]  D E Kuhl,et al.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.

[41]  D. Guilloteau,et al.  Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease , 1999, Synapse.

[42]  Jesper L. R. Andersson,et al.  A template for spatial normalisation of MR images of the rat brain , 2003, Journal of Neuroscience Methods.